i3 Pharamaceuticals, LLC is a modern pharmaceutical company that was established in September 2015. Their mission is to research, develop and manufacture treatments that are typically difficult to manufacture for a variety of reasons.
Technologically focused, i3’s core values are insight, ingenuity and integrity, with an uncompromising dedication to quality.
i3 Pharmaceuticals was founded in September 2015 by Douglas S. Hamilton (formerly or Bristol Mysers Squibb and Sanofi-Aventis), Ram K. Kallur (formerly of Pfizer and URL Pharma, Inc.), Sunil V. Sagi (formerly of SigmaPharma) and Ishari P. Shrestha (formerly of URL Pharma). Their combined experience in research, development and operations as well as their mutual drive for advancement led them to join together in the name of innovation in the pharmaceutical world.
From their beginnings at a small office is Plymouth Meeting, PA to their current 150,00 square foot office in Warmisnter, PA, they have always striven to provide the medical community with state of the art new therapies using technologies other pharmaceutical companies did not have the specialized expertise to work with.
In June 2018, after extensive clinicla trials, i3 filed its first ANDA with the U.S. Food & Drug administration for a new, first-to-market product.